Tirzepatide vs Retatrutide
Dual GIP/GLP-1 Receptor Agonist · Triple GLP-1/GIP/Glucagon Receptor Agonist (investigational)
Here is how these two compounds compare, based on published research, not marketing claims.
Tirzepatide
FDA-approved dual GIP and GLP-1 receptor agonist (marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management). The current FDA-approved standard for largest mean body weight reduction.
Retatrutide
Investigational triple-receptor agonist (GLP-1, GIP, glucagon) in Phase III development. TRIUMPH-4 reported the largest mean body weight reduction in any controlled clinical trial; not yet FDA-approved.
Tirzepatide
1849 studies
47 human trials
FDA-Approved
Retatrutide
131 studies
12 human trials
Not FDA-Approved
What it does
Tirzepatide
Activates two appetite-control receptors at once: GLP-1 and GIP. FDA-approved for type 2 diabetes (Mounjaro) and weight management (Zepbound).
Retatrutide
A triple-receptor agonist studied for weight management and type 2 diabetes. Activates three appetite and metabolism receptors at once: GLP-1, GIP, and glucagon. Trial data shows the largest weight-loss effect of any peptide therapeutic published to date. Currently in Phase III development; not yet FDA-approved.
How it works
Tirzepatide
Engineered to bind two natural appetite hormones' receptors at once. The GLP-1 receptor tells the brain the body is full and slows stomach emptying (the same pathway as semaglutide). The GIP receptor adds enhanced fat oxidation and improved lipid metabolism. The dual signal does what GLP-1 alone does, plus the GIP component, which appears to drive the larger weight-loss effect. Like semaglutide, it stays active in the body for about a week, allowing once-weekly dosing.
Retatrutide
An engineered peptide that binds three receptor systems simultaneously. The GLP-1 side reduces appetite and slows gastric emptying (the mechanism semaglutide and tirzepatide use). The GIP side adds enhanced fat metabolism (the mechanism tirzepatide adds beyond GLP-1). The glucagon side adds increased energy expenditure and hepatic fat oxidation, the mechanism that distinguishes retatrutide from earlier GLP-1 medications. The combined triple action appears to drive the larger weight-loss numbers seen in published trials.
How often
Tirzepatide
FDA labeling specifies once-weekly subcutaneous injection from a pre-filled pen. The SURPASS trial protocols (type 2 diabetes) and SURMOUNT trial protocols (chronic weight management) used gradual dose titration over several months, which the FDA labeling notes is associated with improved GI tolerability. Tirzepatide is marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
Retatrutide
Trial protocols across the TRIUMPH Phase III program use once-weekly subcutaneous injection. The TRIUMPH-4 trial ran 68 weeks; the Phase II obesity trial (Jastreboff et al. 2023, NEJM) ran 48 weeks; the Phase II type 2 diabetes trial (Rosenstock et al. 2023, Lancet) tested four ascending doses against placebo. Six remaining TRIUMPH Phase III trials are still reading out as of 2026. Retatrutide is not yet FDA-approved; clinical availability is restricted to investigational protocols.
How strong
Tirzepatide
The largest weight-loss effect of any FDA-approved peptide to date. In the SURMOUNT-1 trial, average weight loss reached 22.5% at the highest dose over 72 weeks. The effect builds as the dose titrates up.
Retatrutide
Phase II trials reported up to 24.2% mean body weight reduction at the 12 mg dose over 48 weeks (Jastreboff et al. 2023, NEJM). The TRIUMPH-4 Phase III trial reported 28.7% mean body weight reduction at the 12 mg dose over 68 weeks in adults with obesity and knee osteoarthritis, the largest weight-loss outcome reported in a controlled clinical trial. Six remaining TRIUMPH Phase III trials are still reading out across additional populations.
Main tradeoff
Tirzepatide
Larger average weight loss than semaglutide in head-to-head trials (SURPASS-2). Cardiovascular outcomes data is still maturing: semaglutide has SELECT, tirzepatide's parallel trial (SURPASS-CVOT) is ongoing. Less long-term safety data overall because tirzepatide is the newer of the two compounds. Bone mineral density may decrease modestly with significant weight loss; the effect is class-shared with semaglutide and appears weight-loss-mediated rather than drug-specific (Liu et al. 2026). Particularly relevant for adults at baseline fracture risk.
Retatrutide
Trial data shows retatrutide producing larger mean body weight reduction than tirzepatide in Phase II indirect comparison and TRIUMPH-4 Phase III. The structural difference is FDA approval status: tirzepatide is FDA-approved and clinically available today; retatrutide remains in Phase III development. Less long-term safety data overall because the compound is the newer of the two. TRIUMPH-4 reported a new dysesthesia (abnormal skin sensation) safety signal at higher doses requiring monitoring across the remaining TRIUMPH program. Bone mineral density has not yet been reported in retatrutide trials; whether the class-shared bone-loss-with-weight-loss signal observed in semaglutide and tirzepatide users (Liu et al. 2026) extends to retatrutide is empirically open.
Best for
Tirzepatide
- Adults with overweight or obesity seeking the largest average weight reduction available in trials
- Adults with type 2 diabetes seeking superior HbA1c reduction (SURPASS-2 head-to-head data)
- Clinical contexts willing to use a newer compound with less long-term safety data than semaglutide
Retatrutide
- Research interest in next-generation triple-receptor agonist mechanism
- Awaiting FDA approval for clinical use; monitoring the TRIUMPH Phase III program for population coverage and safety profile
- Patients in TRIUMPH or other retatrutide clinical trials under investigator supervision
How to choose
A good fit for Tirzepatide
- Clinical decision today: tirzepatide is FDA-approved (Mounjaro for type 2 diabetes, Zepbound for chronic weight management) and clinically available
- Insurance coverage and physician prescribing pathways exist for the FDA-approved indications
- Established post-marketing safety data and pharmacovigilance through Eli Lilly's reporting channels
- Decision contexts where clinical availability outweighs the larger weight-loss numbers retatrutide produced in trials
A good fit for Retatrutide
- Research interest in the next-generation triple-receptor agonist mechanism
- Monitoring the TRIUMPH Phase III program for clinical adoption when FDA approval lands
- Participation in retatrutide clinical trials under investigator supervision
- Decision contexts where the compound's research-stage status is itself the primary consideration, not whether to pursue treatment today
Consider both across time
Tirzepatide and retatrutide represent two consecutive generations of GLP-1-class metabolic medications. Tirzepatide is FDA-approved and clinically available; retatrutide is in Phase III development with TRIUMPH-4 published and six remaining trials reading out. Trial data shows retatrutide producing larger mean body weight reduction than tirzepatide in Phase II indirect comparison and TRIUMPH-4 Phase III, but FDA approval is the structural difference between the two evidence bases as of today. For the current FDA-approved comparison decision, see Semaglutide vs Tirzepatide. For the broader weight-loss-class landscape including retatrutide, see Semaglutide vs Tirzepatide vs Retatrutide.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GLP-1 Receptor
- GIP Receptor
- GLP-1 Receptor activates Dual GIP + GLP-1 Signaling; GIP Receptor activates Dual GIP + GLP-1 Signaling
- Dual GIP + GLP-1 Signaling connects to Appetite + Fat Metabolism
- Appetite + Fat Metabolism connects to Weight + Glycemic Outcomes
- Glucagon Receptor
- GLP-1 Receptor activates Appetite Suppression
- GIP Receptor activates Insulin Sensitivity
- Glucagon Receptor activates Hepatic Fat Oxidation
- Appetite Suppression connects to Metabolic Regulation; Insulin Sensitivity connects to Metabolic Regulation
- Hepatic Fat Oxidation connects to Energy Expenditure
Tirzepatide activates two receptors at once: GLP-1 (appetite suppression, gastric emptying) and GIP (enhanced fat metabolism).
Retatrutide activates three receptors at once: GLP-1, GIP, and glucagon. The glucagon side adds increased energy expenditure and hepatic fat oxidation.
Research Evidence
Tirzepatide sits at PSI's highest evidence tier (FDA Approved), with the SURPASS program establishing type 2 diabetes efficacy and the SURMOUNT program establishing chronic weight management efficacy. Retatrutide sits at PSI's Human Trials tier: Phase II trials in obesity (Jastreboff et al. 2023, NEJM, 24.2% mean body weight reduction at 12 mg over 48 weeks) and type 2 diabetes (Rosenstock et al. 2023, Lancet) plus the foundational preclinical characterization (Coskun et al. 2022, Cell Metab). The TRIUMPH-4 Phase III trial (2026) reported 28.7% mean body weight reduction at the 12 mg dose over 68 weeks in adults with obesity and knee osteoarthritis. Six remaining TRIUMPH Phase III trials are still reading out across additional populations. The structural difference between the two evidence bases as of today is FDA approval status: tirzepatide is approved, retatrutide remains in Phase III development.
- 1.
For clinical decisions today on obesity or type 2 diabetes treatment, tirzepatide is the FDA-approved option (Mounjaro for type 2 diabetes, Zepbound for chronic weight management).
- 2.
For research interest in next-generation triple-receptor agonist mechanisms, retatrutide trial data shows larger weight-loss magnitude than tirzepatide, with a new dysesthesia safety signal at higher doses requiring monitoring.
- 3.
For the broader weight-loss-class landscape comparison including semaglutide alongside both compounds, see the three-way comparison page.
- 4.
Clinical participation in retatrutide trials requires investigator supervision through the TRIUMPH program or other Phase III protocols.
Key Limitations
- •Direct head-to-head trials between tirzepatide and retatrutide have not been published; magnitude comparisons rely on indirect comparison across separate Phase II and Phase III programs.
- •Six of the seven TRIUMPH Phase III trials are still reading out; retatrutide's broader population coverage and safety profile is not yet fully characterized.
- •Retatrutide is not FDA-approved as of 2026; clinical availability is restricted to investigational protocols.
- •Cardiovascular outcomes data is not yet available for either compound's full indication landscape; tirzepatide's SURPASS-CVOT trial is ongoing, retatrutide has no comparable trial reported.
- •Bone density has not been reported in retatrutide trials; the class-shared signal observed in semaglutide and tirzepatide users may or may not extend.
- •Compounded versions of both active ingredients are not FDA-approved and are subject to pharmacy regulations that have changed multiple times since 2023.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Tirzepatide
"Mounjaro is stronger than Ozempic for weight loss"
Supported by evidence
"The dual agonist mechanism is why it works better"
Supported by evidence
"Tirzepatide has fewer GI side effects than semaglutide"
Plausible but limited comparison data
Retatrutide
"Retatrutide will make Ozempic and Mounjaro obsolete"
Plausible but premature
"The triple agonist mechanism is a game-changer"
Supported by evidence
"Retatrutide causes a weird tingling skin sensation"
Supported by evidence
Safety Comparison
Tirzepatide carries the FDA boxed warning for thyroid C-cell tumors based on rodent studies and the GLP-1 class side effect profile (nausea, vomiting, diarrhea, usually transient and dose-dependent). Long-term post-marketing data has accumulated since 2022 FDA approval. Retatrutide trial data shows GI side effects similar in pattern to GLP-1 agonists, with the addition of a new dysesthesia (abnormal skin sensation) safety signal at higher doses observed in TRIUMPH-4, requiring continued monitoring across the remaining TRIUMPH Phase III program. On bone density: Liu et al. 2026 (J Clin Endocrinol Metab) reported modest BMD loss in semaglutide and tirzepatide users that correlated with weight loss within the GLP-1 RA group; the study did not cover retatrutide. Whether the class-shared bone-loss-with-weight-loss signal extends to retatrutide is empirically open and worth monitoring as TRIUMPH program data matures, particularly given retatrutide's larger weight-loss outcomes. Compounded versions of either active ingredient are not FDA-approved and have been associated with dosing errors and quality concerns outside the FDA-regulated supply chain.
Tirzepatide
Well-characterized safety profile from the SURPASS and SURMOUNT programs. Most common adverse events are GI: nausea, vomiting, diarrhea, typically transient and dose-dependent. FDA boxed warning for thyroid C-cell tumors based on rodent studies; clinical relevance in humans debated.
Retatrutide
Trial-observed safety profile from Phase II and the TRIUMPH-4 Phase III trial. GI side effects similar in pattern to GLP-1 agonists. New dysesthesia (abnormal skin sensation) safety signal observed at higher doses in TRIUMPH-4 requires continued monitoring across the remaining TRIUMPH Phase III program.
What the Research Suggests
Tirzepatide and retatrutide represent two consecutive generations of GLP-1-class metabolic medications. The choice today is structural rather than purely clinical: tirzepatide is FDA-approved and clinically available; retatrutide is investigational and not yet available outside trial protocols. Trial data shows retatrutide producing larger mean body weight reduction than tirzepatide across published trials, but FDA approval is the structural difference between the two evidence bases as of today. PSI does not speculate on retatrutide's regulatory timeline beyond what Eli Lilly publicly indicates. For the appropriate clinical comparison among FDA-approved options, see the semaglutide-vs-tirzepatide page; for the broader weight-loss-class landscape including retatrutide, see the three-way comparison.